AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$INM

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $57K of INM (indirect holdings)

ADAR1 Capital Management, LLC purchased 42,920 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.33 ($1.33–$1.33) across 3 trades over 2026-10-01 to 2026-10-05. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting
SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel
Published Oct 5, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INM
Neutral
high confidence
Mentioned
$INM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INMNeutralLow
01

Why it matters

The filing adds a new data point about insider ownership but the transaction size is too small to affect price materially.

02

Market read

The insider purchase is a routine filing with limited trading relevance.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed could make the insider buy more meaningful.

Relevance 4/10Novelty 3/10Timing: after-market filing on 2026-10-05

Background

Form 4 disclosures are primary-source filings that report insider transactions. ADAR1 Capital Management, a 10% owner, increased its stake in INM.

Company-level read

Ticker impact

$INMNeutralHigh confidence
Context

SEC Form 4 filing shows ADAR1 Capital Management purchased 42,920 shares of InMed Pharmaceuticals (INM) for $57,080.

Expected impact

slight upward pressure as the market prices in the insider buy

Evidence & confidence

The transaction is modest in size ($57K) and represents a 0.06% increase in holdings; such small buys rarely cause significant price moves.

Market effects

Sector

Minimal impact on the biotech/pharma sector; insider activity is routine.

Regional

No regional effect; the filing is specific to the company.

Global

Limited to investors tracking INM; no broader market relevance.

Counterpoint

What could challenge this read

The purchase could be a tactical move unrelated to fundamentals, so traders should not assume bullish sentiment.

Key entities

  • company
    InMed Pharmaceuticals Inc.

    Biopharmaceutical company listed on Nasdaq under ticker INM.

  • investment_firm
    ADAR1 Capital Management, LLC

    Investment manager and 10% owner of INM.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INM insider trading history →

Related articles

OCT 27
$INMMed

InMed Pharmaceuticals: InMed Announces CVR Distribution Record Date in Connection with Proposed Merger

InMed Pharmaceuticals (NASDAQ: INM) set November 5, 2026, as the record date for distributing contingent value rights (CVRs) to shareholders, pending approval of the merger with Mentari Therapeutics and shareholder approval of the Return of Capital Proposal at the November 4, 2026, meeting. The CVRs will be issued under a CVR Agreement, with each shareholder receiving one CVR per common share held as of the record date, but no CVRs will be issued for shares from stock options.

finanznachrichten.de1 min
SEP 18
$INMMed

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Compliance

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Nasdaq: INM c/o Norton Rose Fulbright Canada LLP Suite 1800-510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equi

SEC EDGAR 8-K2 min
SEP 9
$INMMed

InMed Pharmaceuticals: InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

InMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.

finanznachrichten.de2 min
JUL 22
$INMMed

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

benzinga.com4 min
JUL 6
$INMMed

InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

finanznachrichten.de3 min